Updated ASCO Therapy Guideline for Advanced HER2-Positive BC
The American Society of Clinical Oncology (ASCO) recently updated its guideline on systematic therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC) to reflect data that were published between 2016 and 2021. A previous update had been issued in 2018. Learn more about the new recommendations that were provided in this guideline.

Goserelin, Tamoxifen Treatment Concerns in Premenopausal Women
Goserelin, a gonadotropin-releasing hormone agonist, is administered along with tamoxifen for ovarian ablation in pre- or perimenopausal women with breast cancer (BC). Goserelin suppresses the release of follicle-stimulating hormone and luteinizing hormone from the pituitary, resulting in reduced estradiol production and secretion. However, the benefit of the coadministration of goserelin and tamoxifen has been called into question by studies. Read more.

BC Treatment and Effect on Fertility Preservation
Infertility in young breast cancer (BC) patients, which often results from early menopause induced by chemotherapeutic agents, is a major source of distress in this population. Effects to preserve fertility can lead to increased quality of life for those who desire to have children after a BC diagnosis. However, concern exists whether fertility preservation methods can increase the risk of death. Read more.